Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02720445 · ClinicalTrials.gov registry record · Phase 2
Memory Improvement Through Nicotine Dosing (MIND) Study
A Phase 2 study, sponsored by University of Southern California.
- Completed
- Registry status
- Phase 2
- Development phase
- 348
- Enrollment target
NCT02720445: Completed Phase 2 study, sponsored by University of Southern California.
NCT02720445 is a Phase 2 study that has completed, run by University of Southern California. The registered enrollment target is 348 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (162% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02720445, a Phase 2 study, has completed, sponsored by University of Southern California.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 348 participants
- Enrollment target
Study Summary
The purpose of the study is to see if daily transdermal nicotine is able to produce a significant cognitive, clinical and functional improvement in participants with MCI. Neuronal nicotinic receptors have long been known to play a critical role in memory function in preclinical studies, with nicotine improving attention, learning, and memory function. The study will enroll 380 participants for a 2 year period. Participants will be randomized (50:50) to either the transdermal nicotine, beginning at 7mg/day, and increasing to 21mg/day, or placebo skin patch.
Interventions
- DRUG Placebo Patch
- DRUG Nicotine Transdermal Patch
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 348 participants |
| Start Date | 2017-01-13 |
| Est. Completion | 2025-09-16 |
| Phase | Phase 2 |
What the finished NCT02720445 record still lists
NCT02720445 is an interventional study that assigns participants to a tested intervention. The registered 348 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (162% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo Patch is the first listed.
NCT02720445 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02720445 about?
NCT02720445 is a clinical study titled "Memory Improvement Through Nicotine Dosing (MIND) Study". The purpose of the study is to see if daily transdermal nicotine is able to produce a significant cognitive, clinical and functional improvement in participants with MCI. Neuronal nicotinic receptors have long been known to play a critical role in memory function in preclinical studies, with nicotin...
What is the current status of trial NCT02720445?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 348 participants. The study started on 2017-01-13. Estimated completion is 2025-09-16.
What interventions are being tested in trial NCT02720445?
The interventions under investigation include: Placebo Patch (DRUG), Nicotine Transdermal Patch (DRUG).
Who is sponsoring clinical trial NCT02720445?
This trial is sponsored by University of Southern California, which has 617 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02720445's enrollment target sits among peer trials
348 136th of 2000 higher than 1,865 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04041479 · 348 participants · Phase 3
Biomarker-guided rTMS for Treatment Resistant Depression
- NCT04530565 · 348 participants · Phase 3
Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults
- NCT05428735 · 348 participants · NA
The DRAGON 2 Trial
- NCT05787379 · 348 participants · NA
Care for Veterans Post-COVID-19
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI